Back to top
more

Surmodics (SRDX)

(Real Time Quote from BATS)

$38.42 USD

38.42
100,651

-0.07 (-0.18%)

Updated Nov 7, 2024 01:53 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Medtronic's Growth Across All Lines Aid, Rising Costs Ail

by Zacks Equity Research

Of late, Medtronic (MDT) succeeds in delivering solid top-line growth at CER, backed by balanced growth across major business operation.

Myriad Genetics Posts Positive Adjusted Vectra Test Data

by Zacks Equity Research

The key finding of Myriad Genetics' (MYGN) study proves that the adjusted Vectra score beats all traditional measures of disease activity to predict radiographic progression in RA patients.

SYK vs. SRDX: Which MedTech Stock Should Investors Pick?

by Zacks Equity Research

Surmodics (SRDX) scores higher than Stryker (SYK) in terms of current-year revenue projections and fundamentals.

Here's Why You Should Buy Integer Holdings (ITGR) Stock Now

by Zacks Equity Research

As a result of continued efforts to streamline operations, Integer Holdings (ITGR) has been registering strong profits over the last couple of quarters.

Here's Why You Should Invest in Genomic Health (GHDX) Now

by Zacks Equity Research

Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now expanding considerably in the international arena.

Hill-Rom Grows on Acquisitions, Asia Pacific Sales Drop

by Zacks Equity Research

Hill-Rom (HRC) is actively pursuing buyouts to accelerate growth across five key clinical areas.

Here's Why You Should Invest in Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker (SYK) continues to gain from its Mako robotics platform, which has been the key driver of the company's core Orthopaedic segment.

Walgreens (WBA) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Walgreens' (WBA) retail Pharmacy USA division witnessed comparable prescription growth and benefited from a strong retail prescription market.

Walgreens-Alphabet Join Forces to Control Healthcare Costs

by Zacks Equity Research

Walgreens (WBA) and Alphabet's arm Verily to start a medication adherence pilot project that will deploy equipment and other methods to improve adherence.

Here's Why You Should Invest in STERIS (STE) Stock Right Now

by Zacks Equity Research

With the acquisition of U.K.-based outsourced sterilization services provider Synergy Health, STERIS (STE) has become the global leader in infection prevention and sterilization.

Here's Why You Should Hold HealthEquity (HQY) Stock for Now

by Zacks Equity Research

HealthEquity's (HQY) fiscal third-quarter results hold promise while competition is stiff.

Medtronic's Mazor Buyout Creates a New Spine Surgery Major

by Zacks Equity Research

With the acquisition of Mazor Robotics, Medtronic (MDT) expects to offer a fully-integrated procedural solution for surgical planning, execution and confirmation.

Baxter Stock up on Launch of Disposable Curved Applicator

by Zacks Equity Research

Baxter's (BAX) wide array of surgical products see lucrative market prospects.

Surmodics Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Surmodics has been struggling lately, but the selling pressure may be coming to an end soon.

GNC Holdings Global Business Strong, Same Store Sales Weak

by Zacks Equity Research

GNC Holdings' (GNC) domestic franchise revenues worsen due to soft retail same store sales and fewer franchise stores.

Here's Why You Should Hold Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies' (COO) strong CVI segment favors the stock while a soft Fertility unit raises concern.

Here's Why You Should Buy Haemonetics (HAE) Stock Right Now

by Zacks Equity Research

Haemonetics (HAE) continues to witness strong growth in Plasma franchise.

Cerner's (CERN) Millennium Picked by Mid-Valley Hospital

by Zacks Equity Research

Cerner's (CERN) EHR platforms have seen a series of developments in recent times.

Are ABMD & DXCM Neck and Neck? Let's Take a Closer Look

by Zacks Equity Research

DexCom (DXCM) scores higher than Abiomed (ABMD) when it comes to current-year revenue projections and fundamentals.

Hologic's (HOLX) New Offering to Revitalize Cynosure Division

by Zacks Equity Research

The latest launch along with certain new developments is expected to boost top-line contribution from Hologic's (HOLX) Cynosure division in the near term.

Bruker Profits from NANO & CALID, New Buyout Holds Promise

by Zacks Equity Research

Bruker (BRKR) looks to gain from high demand for ADVANCE X-ray and nano-analysis products. The CALID Group also raises hope with high-single digit robust year-to-date revenues.

Thermo Fisher (TMO) Rides on New Buyouts and APAC Strength

by Zacks Equity Research

We are upbeat about Thermo Fisher's (TMO) recent buyout of Advanced Bioprocessing business, which will add complementary cell culture products to the company's bioproduction suit.

Varian Medical's Eclipse Picked by Paul Scherrer Institute

by Zacks Equity Research

Varian Medical's (VAR) latest developments fortify its foothold in the global cancer therapeutics market.

Here's Why You Should Hold Baxter International (BAX) Now

by Zacks Equity Research

Baxter's (BAX) recent string of developments boost the stock while segmental softness is a concern.

Edwards Lifesciences Advances in AI With Bay Labs Tie-Up

by Zacks Equity Research

Through the tie-up, Edwards Lifesciences (EW) aims at improving detection of heart diseases and enhancing quality by using Bay Labs' ability to apply AI to cardiovascular imaging.